Plus   Neg

BD Announces New COVID-19 Data Reporting Capabilities Of BD Synapsys Informatics

Medical technology company Becton, Dickinson and Co. or BD (BDX) on Monday announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys Informatics.

BD Synapsys Informatics is an optional integrated informatics solution available to customers using the BD Veritor Plus System, a portable instrument delivering SARS-CoV-2 antigen test results in about 15 minutes, and the BD MAX System, a molecular diagnostic platform returning results in two to three hours.

Both BD Veritor and BD MAX systems have been granted Emergency Use Authorization or EUA by the U.S. Food and Drug Administration (FDA) to perform SARS-CoV-2 diagnostic testing.

According to the company, the BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and BD MAX systems.

The solution offers configured reporting capabilities that will enable customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security or CARES Act.

The CARES Act requires COVID-19 testing facilities to report testing data to local and federal health authorities daily, including the number of tests performed, results and key patient demographics. BD noted that additional configured reports can be developed, as required.

Used with the BD Veritor Plus System and the BD Max System, the BD Synapsys Informatics 3.84 solution will allow customers to export all SARS-CoV-2 test results in a single daily report.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow. Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022. The company said somatrogon is a long-acting recombinant... German telecom giant Deutsche Telekom AG reported Friday strong growth in fourth-quarter profit mainly driven by T-Mobile US results following the takeover of the competitor Sprint. Looking ahead for fiscal 2021, the company projects higher adjusted EBITDA AL, a key earnings metric.
Follow RTT